Novel Antibacterial and Anticancer Compounds for Treating Drug-Resistant Infections and Folate-Dependent Tumors

Background

The field of antibacterial drug development is at a critical juncture due to the escalating threat of antibiotic-resistant bacteria. Since the introduction of most major antibiotic classes in the mid-20th century, the pipeline for new antibiotics has stagnated, while resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA) and drug-resistant Neisseria gonorrhoeae have proliferated. This stagnation, coupled with the rapid evolution of resistance mechanisms among pathogens, has created an urgent need for new antibacterial agents, particularly those that operate through mechanisms of action (MOAs) distinct from existing drugs. The emergence of multi-drug resistant organisms in both hospital and community settings underscores the necessity for innovative solutions that can effectively target these pathogens and reduce the global burden of infectious diseases.

Current approaches to antibiotic discovery and development face significant limitations. Traditional methods often rely on modifying existing antibiotic scaffolds, which can lead to cross-resistance and diminished long-term efficacy. Many screening strategies are biased toward known targets or fail to account for the complex permeability barriers of gram-negative bacteria, resulting in a low yield of truly novel compounds. Furthermore, the lack of high-throughput, mechanism-focused screening tools has hindered the identification of agents with unique MOAs. As a result, most new antibiotics entering the market are derivatives of established classes, offering only incremental improvements and leaving critical gaps in the fight against resistant infections. This situation is exacerbated by the pharmaceutical industry’s reduced investment in antibiotic research, driven by economic and regulatory challenges, further impeding the discovery of groundbreaking antibacterial therapies.

Technology

This technology centers on the discovery and application of a new class of antibacterial compounds that are effective against both gram-positive and gram-negative bacteria, including multi-drug resistant pathogens such as MRSA and N. gonorrhoeae. The compounds—such as SCH 79797, Triflupromazine, and ONO-RS-82—were identified through high-throughput whole-cell screening and advanced bacterial cytological profiling, which enabled the selection of agents with unique and previously uncharacterized mechanisms of action. These agents exhibit potent antibacterial activity at low minimum inhibitory concentrations (typically between 1 µg/ml and 10 µg/ml), and some, like SCH 79797, also demonstrate anticancer properties by targeting folate metabolism in cancer cells. The technology includes methods for treating bacterial infections by administering these compounds, either alone or in combination with suitable carriers, and extends to the use of SCH 79797 for cancer therapy.

What differentiates this technology is its systematic approach to overcoming the stagnation in antibiotic development and the growing threat of antibiotic resistance. Unlike traditional antibiotics, these compounds were selected not only for their potency but also for their novel mechanisms, such as disrupting bacterial folate biosynthesis or inducing unique cellular stress responses. The use of high-content cytological profiling and principal component analysis allowed for the identification of agents with distinct phenotypic effects, minimizing cross-resistance with existing drugs. Furthermore, resistance studies showed that compounds like SCH 79797 have a low propensity for resistance development, a critical advantage in clinical settings. The broad-spectrum efficacy, novel targets, and dual antibacterial-anticancer potential make this technology a significant advancement in the fight against resistant infections and certain cancers.

Benefits

• Effective against a broad spectrum of gram-positive and gram-negative bacteria, including multi-drug resistant strains like MRSA and *N. gonorrhoeae*
• Novel mechanisms of action, such as disruption of bacterial folate biosynthesis, reducing cross-resistance with existing antibiotics
• Low minimum inhibitory concentrations (MICs), often below 1 µg/ml, indicating high potency
• Reduced likelihood of resistance development compared to traditional antibiotics
• Identified through high-throughput whole-cell screening and bacterial cytological profiling for precise mechanism elucidation
• Some compounds, like SCH 79797, also exhibit anticancer activity by targeting folate metabolism in cancer cells
• Potential for use in treating both bacterial infections and certain cancers, broadening therapeutic applications
• Supported by comprehensive experimental data including metabolomics, gene expression, and resistance profiling

Applications

• Treatment of drug-resistant bacterial infections
• Broad-spectrum hospital infection control
• Adjunct therapy for cancer treatment
• Development of novel antibiotic drugs

Additional info

These antibacterial compositions employ compounds such as SCH 79797, Triflupromazine, and ONO-RS-82 to inhibit gram-positive and gram-negative pathogens, including MRSA and *N. gonorrhoeae*. Discovered via high-throughput whole-cell screening and cytological profiling, these agents function by disrupting folate biosynthesis or triggering Cpx envelope stress responses. Exhibiting minimum inhibitory concentrations between 1–10 µg/ml, certain molecules also demonstrate anticancer potential by inhibiting folate metabolism in malignant cells.